67828-44-8

Basic information

• Product Name: 2,4-DIHYDROXY-5-CHLOROBENZOIC ACID
• Synonyms: 5-CHLORO-BETA-RESORCYLIC ACID;5-CHLORO-2,4-DIHYDROXYBENZOIC ACID;2,4-DIHYDROXY-5-CHLOROBENZOIC ACID;5-chloro-beta-resorcylicaci;5-chloro-4-hydroxysalicylic acid;5-Chloro-β-resorcylic acid;Benzoic acid, 5-chloro-2,4-dihydroxy-;beta-Resorcylic acid, 5-chloro-
• CAS NO: 67828-44-8
• Molecular Formula: C₇H₅ClO₄
• Molecular Weight: 188.57
• EINECS: 267-267-5
• Mol File: 67828-44-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 224-225℃
• Boiling Point: 411℃
• Flash Point: 203℃
• Appearance: /
• Density: 1.702
• Vapor Pressure: 1.69E-07mmHg at 25°C
• Refractive Index: 1.679
• PKA: 2.86±0.10(Predicted)
• CAS DataBase Reference: 2,4-DIHYDROXY-5-CHLOROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIHYDROXY-5-CHLOROBENZOIC ACID(67828-44-8)
• EPA Substance Registry System: 2,4-DIHYDROXY-5-CHLOROBENZOIC ACID(67828-44-8)

Safety Data

• Hazardous Substances Data: 67828-44-8(Hazardous Substances Data)

Usage

General Description

2,4-Dihydroxy-5-chlorobenzoic acid is a chemical compound with the molecular formula C7H5ClO4. It is a derivative of benzoic acid and contains two hydroxyl groups and a chlorine atom attached to the benzene ring. 2,4-DIHYDROXY-5-CHLOROBENZOIC ACID is commonly used as an intermediate in the synthesis of pharmaceuticals, dyes, and other organic compounds. It is also known to have antimicrobial and herbicidal properties, making it useful in agricultural and industrial applications. Additionally, 2,4-dihydroxy-5-chlorobenzoic acid has been studied for its potential antioxidant and anti-inflammatory properties, showing promise for use in the development of new medications.

InChI:InChI=1/C7H5ClO4/c8-4-1-3(7(11)12)5(9)2-6(4)10/h1-2,9-10H,(H,11,12)

Upstream product

• 829-20-9 2',4'-dimethoxyacetophenone 
• 108-46-3 recorcinol 
• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 1378866-39-7 5-chloro-2-hydroxy-4-methoxybenzoic acid 
• 67828-69-7 methyl 5-chloro-2,4-dihydroxybenzoate 
• 95-88-5 4-Chlororesorcinol 
• 7732-18-5 water 
• 89-86-1 4-hydroxysalicylic acid 
• 7782-50-5 chlorine 
• 64-19-7 acetic acid 
• 7791-25-5 sulfuryl dichloride 
• 60-29-7 diethyl ether 
• 23053-75-0 4-Chlor-6-chloracetylresorcin-dimethylether 

Downstream Products

• 644971-05-1 5-chloro-2-hydroxy-4-(4-methoxybenzyloxy)benzoic acid methyl ester 
• 102541-32-2 5-chloro-2,4-dihydroxy-3-propionyl-benzoic acid 
• 95-88-5 4-Chlororesorcinol 
• 99854-28-1 3-butyryl-5-chloro-2,4-dihydroxy-benzoic acid 
• 912545-04-1 2,4-bis(benzyloxy)-5-chlorobenzoic acid 

Relevant articles and documents

-

-

Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors

Heat shock protein 90 (Hsp90) is a ubiquitous molecular chaperone that is responsible for the stabilization and maturation of many oncogenic proteins. Therefore, Hsp90 has emerged as an attractive target in the field of cancer chemotherapy. In this study, we report the design, synthesis, and biological evaluation of a series of Hsp90 inhibitors. In particular, compound 30f shows a significant Hsp90α inhibitory activity with IC50 value of 5.3 nM and an excellent growth inhibition with GI50 value of 0.42 μM against non-small cell lung cancer cells, H1975. Compound 30f effectively reduces the expression levels of Hsp90 client proteins including Her2, EGFR, Met, Akt, and c-Raf. Consequently, compound 30f promotes substantial cleavages of PARP, Caspase 3, and Caspase 8, indicating that 30f induces cancer cell death via apoptotic pathway. Moreover, cytochrome P450 assay indicates that compound 30f has weak inhibitory effect on the activities of five major P450 isoforms (IC50 > 5 μM for 1A2, 2C9, 2C19, 2D6, and 3A), suggesting that clinical interactions between 30f and the substrate drugs of the five major P450 isoforms are not expected. Compound 30f also inhibits the tumor growth in a mouse xenograft model bearing subcutaneous H1975 without noticeable abnormal behavior and body weight changes. The immunostaining and western immunoblot analysis of EGFR, Met, Akt in xenograft tissue sections of tumor further demonstrate a good agreement with the in vitro results.

NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of formula (I) wherein R1, R3, R4, R5, R6, R7, and R10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.